Market Overview

UPDATE: Jefferies Downgrades Halozyme Therapeutics to Underperform on FDA Headwinds


Jefferies reduced its rating on Halozyme Therapeutics (NASDAQ: HALO) from Hold to Underperform and cut its price target from $8 to $3 following an FDA hold on clinical trials of an important growth driver to the company.

Jefferies said, "As expected HyQ gets CRL, but more importantly, FDA puts a clinical hold on rHuPH20 trials for HyQ & Cinryze. Given HALO's value is entirely based on its rHuPH20 platform, this raises significant uncertainty on its future (unlikely additional partnership opportunity, conceivable termination of BAX/VPHM deals). Even if Roche's SC Herceptin/SC MabThera get thru U approval, commercial potential is small from our previous survey data."

Halozyme Therapeutics closed at $8.56 on Wednesday.

Latest Ratings for HALO

Feb 2020BarclaysMaintainsEqual-Weight
Feb 2020JP MorganMaintainsOverweight
Feb 2020Piper SandlerUpgradesNeutralOverweight

View More Analyst Ratings for HALO
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Downgrades Intraday Update Analyst Ratings


Related Articles (HALO)

View Comments and Join the Discussion!

Latest Ratings

SOLOAegis CapitalMaintains4.0
TBPHHC Wainwright & Co.Maintains32.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at